Toll Free: 1-888-928-9744

ReGenX Biosciences, LLC - Product Pipeline Review - 2014

Published: Dec, 2014 | Pages: 35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

ReGenX Biosciences, LLC - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'ReGenX Biosciences, LLC - Product Pipeline Review - 2014', provides an overview of the ReGenX Biosciences, LLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ReGenX Biosciences, LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ReGenX Biosciences, LLC including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ReGenX Biosciences, LLC's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the ReGenX Biosciences, LLC's pipeline products

Reasons to buy

- Evaluate ReGenX Biosciences, LLC's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ReGenX Biosciences, LLC in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ReGenX Biosciences, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ReGenX Biosciences, LLC and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ReGenX Biosciences, LLC
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ReGenX Biosciences, LLC and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
ReGenX Biosciences, LLC Snapshot 5
ReGenX Biosciences, LLC Overview 5
Key Information 5
Key Facts 5
ReGenX Biosciences, LLC - Research and Development Overview 6
Key Therapeutic Areas 6
ReGenX Biosciences, LLC - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
ReGenX Biosciences, LLC - Pipeline Products Glance 14
ReGenX Biosciences, LLC - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
ReGenX Biosciences, LLC - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
ReGenX Biosciences, LLC - Drug Profiles 16
Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Gene Therapy to Activate Factor IX for Hemophilia B 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Gene Therapy to Activate Tripeptidyl Peptidase 1 for Batten Disease 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
AP-22594 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Gene Therapy for Alzheimer's Disease 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gene Therapy for Wet Age-Related Macular Degeneration 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Gene Therapy to Activate Arylsulfatase B for Maroteaux-Lamy Syndrome 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Gene Therapy to Activate Iduronidase for Hurler Syndrome 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Gene Therapy to Activate LDL Receptor for Homozygous Familial Hypercholesterolemia 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis (LCA) 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ReGenX Biosciences, LLC - Pipeline Analysis 28
ReGenX Biosciences, LLC - Pipeline Products by Target 28
ReGenX Biosciences, LLC - Pipeline Products by Route of Administration 29
ReGenX Biosciences, LLC - Pipeline Products by Molecule Type 30
ReGenX Biosciences, LLC - Pipeline Products by Mechanism of Action 31
ReGenX Biosciences, LLC - Recent Pipeline Updates 32
ReGenX Biosciences, LLC - Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35
List of Tables
ReGenX Biosciences, LLC, Key Information 5
ReGenX Biosciences, LLC, Key Facts 5
ReGenX Biosciences, LLC - Pipeline by Indication, 2014 7
ReGenX Biosciences, LLC - Pipeline by Stage of Development, 2014 8
ReGenX Biosciences, LLC - Monotherapy Products in Pipeline, 2014 9
ReGenX Biosciences, LLC - Partnered Products in Pipeline, 2014 10
ReGenX Biosciences, LLC - Partnered Products/ Combination Treatment Modalities, 2014 11
ReGenX Biosciences, LLC - Out-Licensed Products in Pipeline, 2014 12
ReGenX Biosciences, LLC - Out-Licensed Products/ Combination Treatment Modalities, 2014 13
ReGenX Biosciences, LLC - Phase I, 2014 14
ReGenX Biosciences, LLC - Preclinical, 2014 15
ReGenX Biosciences, LLC - Pipeline by Target, 2014 28
ReGenX Biosciences, LLC - Pipeline by Route of Administration, 2014 29
ReGenX Biosciences, LLC - Pipeline by Molecule Type, 2014 30
ReGenX Biosciences, LLC - Pipeline Products by Mechanism of Action, 2014 31
ReGenX Biosciences, LLC - Recent Pipeline Updates, 2014 32 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify